(0.32%) 5 116.17 points
(0.39%) 38 387 points
(0.35%) 15 983 points
(-1.35%) $82.72
(6.19%) $2.04
(-0.05%) $2 346.00
(-0.23%) $27.47
(3.87%) $957.75
(-0.21%) $0.933
(-0.33%) $10.99
(-0.54%) $0.796
(1.65%) $93.39
Live Chart Being Loaded With Signals
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions...
Stats | |
---|---|
Šios dienos apimtis | 1.40M |
Vidutinė apimtis | 4.22M |
Rinkos kapitalizacija | 5.11B |
EPS | €0 ( 2024-02-28 ) |
Kita pelno data | ( €0 ) 2024-05-14 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 93.89 |
ATR14 | €0.00500 (0.06%) |
Tūris Koreliacija
Grifols, S.A. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Grifols, S.A. Koreliacija - Valiuta/Žaliavos
Grifols, S.A. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €6.59B |
Bruto pelnas: | €2.32B (35.24 %) |
EPS: | €0.0873 |
FY | 2023 |
Pajamos: | €6.59B |
Bruto pelnas: | €2.32B (35.24 %) |
EPS: | €0.0873 |
FY | 2022 |
Pajamos: | €6.06B |
Bruto pelnas: | €2.23B (36.80 %) |
EPS: | €0.310 |
FY | 2021 |
Pajamos: | €4.93B |
Bruto pelnas: | €1.96B (39.78 %) |
EPS: | €0.267 |
Financial Reports:
No articles found.
Grifols, S.A.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.